Medicine guide
Incivo
·
- Prescription status not stated
- Antibiotics, antivirals and antifungals taken into the body
- Active substance
- Telaprevir
- Made by
- Janssen-Cilag International
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Incivo, in combination with peginterferon alfa and ribavirin, is indicated for the treatment of genotype-1 chronic hepatitis C in adult patients with compensated liver disease (including cirrhosis): who are treatment naïve; who have previously been treated with interferon alfa (pegylated or non-pegylated) alone or in combination with ribavirin, including relapsers, partial responders and null responders.
From the official label · 2026-09-30 · European Medicines Agency
Details
| Made by | Janssen-Cilag International |
|---|---|
| Active substance | Telaprevir |
| Used in | Antibiotics, antivirals and antifungals taken into the body |
| Classification | J05AE · Antibiotics, antivirals and antifungals taken into the body |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Authorised on | 2011-09-19 |
| Last updated by the regulator | 2016-10-06 |
| EMA product number | EMEA/H/C/002313 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).